The concept was recently examined in a phase I clinical trial, administering nivolumab (IgG4 antibody to PD-1) and ipilimumab (IgG1 antibody to CTLA4) in patients with stage III or IV melanoma. This evidence concerns the gene CTLA4 and melanoma.